Improving combination product development with digital continuity

The fast-growing business of combination products has put pharma companies in a unique position to expand their product pipeline, offering up new opportunities for growth and profitability.

By combining drugs with medical devices, pharma organizations are able to deliver considerable value to patients and healthcare providers, such as improved patient compliance and drug delivery. The complexity of combining devices with drugs, however, requires pharma companies to improve business processes around product development and regulatory compliance. Digital technologies, such as digital thread and modelling and simulation will facilitate high quality, fully compliant and fast product discovery, development and commercialization. 

In this one-hour panel masterclass, pharma-experts will dive into the current barriers that hold many pharma companies back from securing the benefits combination products are set to offer.

Panelists will also explore how digital continuity and virtual twins accelerate and improve innovation in the drug-device arena.

During this masterclass we will answer the following questions:

• Where to start on the drug-device development journey and key activities to avoid.
• What is digital continuity and how it impacts business processes for combination products.
• How to ensure new technology transforms pharma organizations and improves the current way of working.
• If virtual testing is possible.
• How far virtual testing and simulation can be used in the development of combination products.